Glutamine antagonism attenuates physical and cognitive deficits in a model of MS

Kristen R. Hollinger, Matthew D. Smith, Leslie A. Kirby, Eva Prchalova, Jesse Alt, Rana Rais, Peter A. Calabresi, Barbara S. Slusher

Research output: Contribution to journalArticlepeer-review

Abstract

OBJECTIVE: To measure the impact of JHU-083, a novel prodrug of the glutamine antagonist 6-diazo-5-oxo-l-norleucine, on immune cell proliferation and activation, along with physical and cognitive impairments associated with the experimental autoimmune encephalomyelitis (EAE) mouse model of MS. METHODS: Splenic-derived T cells and bone marrow-derived dendritic cells (DCs) were cultured, activated, and treated daily with vehicle or JHU-083. Proliferation and activation were measured via flow cytometry and IncuCyte live cell analysis. C57BL/6 mice were immunized for EAE. Vehicle or JHU-083 was administered orally every other day either from the time of immunization in the prevention paradigm or from the time of disease onset in the treatment paradigm. Disease scores and body weight were monitored. In the treatment paradigm, cognition was evaluated using the Barnes maze test. RESULTS: JHU-083 selectively inhibits T-cell proliferation and decreases T-cell activation, with no effect on DCs. In vivo, orally administered JHU-083 significantly decreases EAE severity in both prevention and treatment paradigms and reverses EAE-induced cognitive impairment. CONCLUSIONS: JHU-083, a well-tolerated, brain penetrable glutamine antagonist, is a promising novel treatment for both the physical and cognitive deficits of MS.

Original languageEnglish (US)
JournalNeurology(R) neuroimmunology & neuroinflammation
Volume6
Issue number6
DOIs
StatePublished - Nov 1 2019

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Glutamine antagonism attenuates physical and cognitive deficits in a model of MS'. Together they form a unique fingerprint.

Cite this